The racial disparity in outcomes in endometrial cancer: Could this be explained on a molecular level?

Schimp, Veronica; Ali-Fehmi, Rouba; Solomon, Liza; Hammoud, Ahmad; Pansare, Vaishali; Morris, R.; Munkarah, Adnan

doi:10.1016/j.ygyno.2006.01.041

Cited by 29 publications

(25 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study confirms that the often-cited racial disparity in clinicopathologic characteristics between Blacks and Whites [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] remains evident despite equal access to care. Moreover, we demonstrate that this racial variation is confined to older women, with Blacks prejudicially enduring non-endometrioid, non-localized, and poorly differentiated tumors.…”

Section: Discussionsupporting

confidence: 76%

“…An analysis of 147 patients diagnosed with endometrial cancer between 1995 and 2001 sought to analyze and compare the molecular profiles in endometrial cancer in White and Black patients using a number of known molecular markers [18]. Black patients had more type II carcinoma than White patients with high p53 protein expression increased significantly among the Black patients (49% vs. 30%, P = 0.035) versus White patients [18].…”

Section: Discussionmentioning

confidence: 99%

“…The American Cancer Society estimated that 43,470 new cases of and 7950 deaths from endometrial cancer would occur during 2010 [1]. While uterine cancer incidence rates are lower among Black women than White women, [2] Blacks are more often diagnosed with aggressive histologic subtypes, advanced tumor stages, and/or higher tumor grades, and they suffer a correspondingly worse prognosis [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21]. Indeed, the disease-specific mortality rate for Black women is nearly double that endured by White women [2].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment

Oliver

Enewold²,

Zhu

et al. 2011

Gynecologic Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment

Oliver

Enewold²,

Zhu

et al. 2011

Gynecologic Oncology

View full text Add to dashboard Cite

“…Both approaches have been associated with excellent pelvic control and survival rates. [44][45][46] Intermediate-risk and Organ-confined High-risk Disease…”

Section: High-risk Diseasementioning

confidence: 99%

Cancer Endometrium: An Update

Kumar¹,

Goel²

2012

Journal of South Asian Federation of Obstetrics and Gynaecology

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecological cancer in developed countries and second most common in developing countries. Its incidence is increasing in postmenopausal women. Factors related to chronic estrogen exposure are associated with a higher incidence. Abnormal uterine bleeding is the cardinal symptom. All women with suspected endometrial cancer require transvaginal ultrasonography and most will undergo endometrial biopsy; more sophisticated radiological examinations are required for preoperative staging. The general approach for treatment of endometrial cancer is hysterectomy, bilateral salpingo-oophorectomy, abdominopelvic washings, lymph node evaluation and maximal surgical cytoreduction for those with advanced disease. Postoperative adjuvant therapy [vaginal brachytherapy, external beam radiation therapy (RT), chemotherapy] may be recommended depending on the estimated risk of recurrence. Individual patient characteristics and surgical as well as pathologic staging are the main factors that are used for postsurgical risk stratification, which in turn, directs the selection of adjuvant treatment.

show abstract

“…On the other hand, higher aromatase levels have been reported in hyperplastic than in normal endometrium (10). Currently, continuous treatment with megestrol acetate is effective in removing proliferative disorders and endometrial hyperplasia without atypia, and but is less effective in cases with atypia (11,12). Several reports have emphasized the possible unfavorable vascular effects of progestins (13) and treatment by progestron can also result in weight gain and mood changes (14).in recent years, several clinical trials on the use of letrozole in the treatment of endometrial hyperplasia has been done, which showed the need for further assessment of the effectiveness of this method.…”

Section: Introductionmentioning

confidence: 99%

Effect of Letrozole on Endometrial Histology in Patients with Disordered Proliferative Endometrium and Simple Hyperplasia

Gharabaghi¹,

Azadeh²,

Tabrizi³

et al. 2014

IJWHR

View full text Add to dashboard Cite

Objectives: This is a preliminary study investigating the efficacy of aromatase inhibitor letrozol on endometrial histology in patients with disordered proliferative endometrium or simple hyperplasia. Materials and Methods: In a randomized clinical trial, 92 patients with abnormal uterine bleeding who had disordered proliferative endometrium or simple hyperplasia in endometrial biopsy, were randomized into case and control groups. patients received 2.5 mg of letrozole daily in case group (n=46) and 40 mg of megestrol acetate daily in control group (n=46) for 3 months. Endometrial biopsy was performed 3 to 4 weeks after completion of therapy to assess response. Results: After intervention in letrozole group, response to treatment was seen in 93% cases (including endometrial atrophy in 58.7% cases and weakly proliferative endometrium in 34.78% cases) and in megestrol group response to treatment was seen in 85% cases (including endometrial atrophy in 41.3% cases and weakly proliferative endometrium in 43.47% cases). The difference between two groups was not statistically significant (P=0.31). Conclusion: The results of this study show that pre and post menopausal women with disordered proliferative endometrium or simple hyperplasia can be successfully treated with letrozole alone. However, due to the lack of significant difference between the two groups, further studies with larger sample size is recommended for better clearance of the topic.

show abstract

The racial disparity in outcomes in endometrial cancer: Could this be explained on a molecular level?

Cited by 29 publications

References 32 publications

Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment

Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment

Cancer Endometrium: An Update

Effect of Letrozole on Endometrial Histology in Patients with Disordered Proliferative Endometrium and Simple Hyperplasia

Contact Info

Product

Resources

About